FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

AI Summary

FDA advisers are currently reviewing the Galleri multicancer-detection blood test developed by Grail, which aims to detect 50 types of cancer early. However, a major study raised concerns due to its failure to detect later-stage cancers effectively.

Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.